Cargando…

Active Surveillance for Intermediate Risk Prostate Cancer

BACKGROUND: Utilization of active surveillance (AS) for prostate cancer is increasing. Optimal selection criteria for this approach are undefined and questions remain on how best to expand inclusion beyond typical men with very low or low risk disease. We sought to review the current experience with...

Descripción completa

Detalles Bibliográficos
Autores principales: Dall'Era, Marc A., Klotz, Laurence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303136/
https://www.ncbi.nlm.nih.gov/pubmed/27801900
http://dx.doi.org/10.1038/pcan.2016.51
_version_ 1782506662122225664
author Dall'Era, Marc A.
Klotz, Laurence
author_facet Dall'Era, Marc A.
Klotz, Laurence
author_sort Dall'Era, Marc A.
collection PubMed
description BACKGROUND: Utilization of active surveillance (AS) for prostate cancer is increasing. Optimal selection criteria for this approach are undefined and questions remain on how best to expand inclusion beyond typical men with very low or low risk disease. We sought to review the current experience with AS for men with intermediate risk features. METHODS: Pubmed was queried for all relevant original publications describing outcomes for men with prostate cancer managed with AS. Outcomes for patients with intermediate risk features as defined by the primary investigators were studied when available and compared with similar risk men undergoing immediate treatment. RESULTS: Cancer specific survival for men managed initially with AS is similar to results published with immediate radical intervention. A total of 5 published AS series describe some outcomes for men with intermediate risk features. Definitions of intermediate risk vary between studies. Men with Gleason 7 disease experience higher rates of clinical progression and are more likely to undergo treatment over time. Intermediate risk men with Gleason 6 disease have similar outcomes to low risk men. Men with Gleason 7 disease appear at higher risk for metastatic disease. Novel technologies including imaging and biomarkers may assist with patient selection and disease surveillance. CONCLUSIONS: The contemporary experiences of AS for men with intermediate risk features suggest that although these men are at higher risk for eventual prostate directed treatment, some are not significantly compromising chances for longer-term cure. Men with more than minimal Gleason pattern 4, however, must be carefully selected and surveyed for early signs of progression and may be at increased risk of metastases. Incorporating information from advanced imaging and biomarker technology will likely individualize future treatment decisions while improving overall surveillance strategies.
format Online
Article
Text
id pubmed-5303136
institution National Center for Biotechnology Information
language English
publishDate 2016
record_format MEDLINE/PubMed
spelling pubmed-53031362017-05-01 Active Surveillance for Intermediate Risk Prostate Cancer Dall'Era, Marc A. Klotz, Laurence Prostate Cancer Prostatic Dis Article BACKGROUND: Utilization of active surveillance (AS) for prostate cancer is increasing. Optimal selection criteria for this approach are undefined and questions remain on how best to expand inclusion beyond typical men with very low or low risk disease. We sought to review the current experience with AS for men with intermediate risk features. METHODS: Pubmed was queried for all relevant original publications describing outcomes for men with prostate cancer managed with AS. Outcomes for patients with intermediate risk features as defined by the primary investigators were studied when available and compared with similar risk men undergoing immediate treatment. RESULTS: Cancer specific survival for men managed initially with AS is similar to results published with immediate radical intervention. A total of 5 published AS series describe some outcomes for men with intermediate risk features. Definitions of intermediate risk vary between studies. Men with Gleason 7 disease experience higher rates of clinical progression and are more likely to undergo treatment over time. Intermediate risk men with Gleason 6 disease have similar outcomes to low risk men. Men with Gleason 7 disease appear at higher risk for metastatic disease. Novel technologies including imaging and biomarkers may assist with patient selection and disease surveillance. CONCLUSIONS: The contemporary experiences of AS for men with intermediate risk features suggest that although these men are at higher risk for eventual prostate directed treatment, some are not significantly compromising chances for longer-term cure. Men with more than minimal Gleason pattern 4, however, must be carefully selected and surveyed for early signs of progression and may be at increased risk of metastases. Incorporating information from advanced imaging and biomarker technology will likely individualize future treatment decisions while improving overall surveillance strategies. 2016-11-01 2017-03 /pmc/articles/PMC5303136/ /pubmed/27801900 http://dx.doi.org/10.1038/pcan.2016.51 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Dall'Era, Marc A.
Klotz, Laurence
Active Surveillance for Intermediate Risk Prostate Cancer
title Active Surveillance for Intermediate Risk Prostate Cancer
title_full Active Surveillance for Intermediate Risk Prostate Cancer
title_fullStr Active Surveillance for Intermediate Risk Prostate Cancer
title_full_unstemmed Active Surveillance for Intermediate Risk Prostate Cancer
title_short Active Surveillance for Intermediate Risk Prostate Cancer
title_sort active surveillance for intermediate risk prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303136/
https://www.ncbi.nlm.nih.gov/pubmed/27801900
http://dx.doi.org/10.1038/pcan.2016.51
work_keys_str_mv AT dalleramarca activesurveillanceforintermediateriskprostatecancer
AT klotzlaurence activesurveillanceforintermediateriskprostatecancer